We have been active in trading during the aftermath of the Iran war. Jim Cramer explains our approach
Jim Cramer explained Tuesday morning why the Investment Club is trying to strike a delicate balance with its moves during…
taking stock
Here's Jim Cramer's Tips for Navigating the Markets During the Iran Conflict
Jim Cramer's advice to investors dealing with the fallout from the US-Israeli attack on Iran: be selective. With stocks initially…
We are adding stock to our Bullpen; resilient to recessions and AI disruption
We added a new Bullpen name during Friday's monthly meeting, and it has minimal economic sensitivity and faces little to…
Danaher is making good use of mergers and acquisitions once again. But we could have had enough
Danaher's days in the portfolio may be numbered. We were once again disappointed after Danaher's latest acquisition plan failed to…
Eli Lilly investors shouldn't worry that rival Novo Nordisk has the first anti-obesity pill on sale
Jim Cramer says not to worry about Novo Nordisk's lead over Club that has Eli Lilly in the obesity pill…
Why Wall Street and Jim Cramer Think Danaher Stock Is 'Ready to Play'
Danaher is finally turning the corner. CNBC's Jim Cramer sees it. Wall Street does it too. Life sciences stocks are…
Eli Lilly's lead in the obesity race has increased. Its recent stock performance says otherwise.
Eli Lilly investors have received some very good news in recent months, with one notable exception regarding the stock's performance.…
Danaher had a disappointing 2024. Your path to success next year passes through Wall Street
Life sciences company Danaher certainly hasn't been an easy stock to buy this year. A wave of new companies going…
Eli Lilly seeks to extend its winning streak in the general market to 6 years
Eli Lilly has outperformed the S&P 500 for five straight years as Wall Street realized its huge opportunity in obesity…
Eli Lilly's obesity drug beats rival in head-to-head trial, where Cramer thinks stock will be next
The new trial data has cemented Club's lead position behind Eli Lilly in the highly competitive anti-obesity drug race. Eli…